

Investigating Recipient Immune and CAR T-cell

Populations during CAR-T Therapy with Multi-omics

Curtis Cai¹*, Raymond Louie¹*, Varsha Balraj², Katherine Jackson², James Ferguson³, Ira Deveson², Mandeep Singh², David Bishop⁴, Kavitha Gowrishankar⁴, Kenneth Micklethwaite⁴, Fabio Luciani¹

- ¹ The Kirby Institute, UNSW
- ² Garvan Institute of Medical Research
- ³ Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- ⁴ The Westmead Institute for Medical Research
- * Contributed equally

Emerging Technologies in Single Cell Research (November 2020)

Single-cell profiling of total immune cell (PBMC) and CAR T-cell populations during immunotherapy

Unpublished, not for distribution

- Donor-derived CAR T-cells with specificity for the CD19 (B cell) antigen were manufactured using the piggyBac transposase system
- We applied single-cell multiomics (transcriptome, proteome, immune receptor) to track immune reconstitution, CAR T-cell responses, and differentiation.





Unpublished, not for distribution

Total immune cell population profiling reveals preand post-infusion reconstitution dynamics



We analysed over 50.000 single cells derived from 4 CAR-T therapy patients at pre-infusion and post-infusion timepoints and observed skewing from monocyte to T cell subsets. (A) Patient sampling timepoints. (B) UMAP of all cells. (C) UMAP portion including cells from the total immune cell population. (D) UMAP portion including only CAR T-cells sequenced following enrichment. (E) Protein expression supports assignment of canonical immune cell subsets in circulation.

Unpublished, not for distribution

Day 7

Day 13

T cell evolution at the transcriptomic and clonotype levels during CAR-T immunotherapy

